Clarify the diagnostic purpose, format and product scope before mapping the regulatory pathway.
IVD Reagent Registration in Bangladesh
Focused regulatory support for in-vitro diagnostic reagents and related diagnostic products, with attention to intended use, product documentation and Bangladesh market-access requirements.
Discuss Your Product →A pathway designed around diagnostic products
IVD products require clear intended-use information and a coherent technical and regulatory file before local submission.
Review product, quality, performance and manufacturer information relevant to the registration file.
Coordinate Bangladesh-side regulatory activities and follow-through for the product.
A structured route from initial review to regulatory follow-through
Assessment
Review the IVD product, intended use and current regulatory status.
Readiness
Identify gaps across technical, performance and manufacturer documentation.
Coordination
Prepare and coordinate the applicable local registration process.
Lifecycle
Support relevant changes, renewals and ongoing regulatory needs.
Organize the diagnostic product documentation
A structured review should confirm which supporting materials are relevant to the specific IVD product.
- Product description and intended diagnostic use
- Manufacturer and quality-system information
- Performance and supporting technical information
- Labeling, instructions and packaging information
- Local representative information where applicable
Before you begin
The regulatory approach depends on the product and applicable classification. IVD-specific intended use and supporting information can affect the submission requirements.
Start with product identity, intended use, manufacturer status, existing approvals and the available technical documentation.
Yes. Support can cover document readiness, local coordination and representation-related requirements where applicable.
Planning to introduce an IVD product in Bangladesh?
Share your product category and current documentation status to start the regulatory discussion.
